AtriCure Inc. (ATRC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$62.48 +1.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $62.56

AtriCure Inc. (ATRC) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $3.18B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $62.55 (+0.12%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510063
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B+
Cash (10)Whales (14)SEC (16)Macro (15)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE+2.3% Base Target
$75 Bull$64 Base$50 Bear
📬 FREE ATRC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATRC)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (63/100 Composite)
🔍 WHY ATRC SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 12.08 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (24% of score)

FRED Regime × Technicals: 99% of 52W Range • RSI-14 at 62.9 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$55.81+0.5% Next Q
Q2 (-2Q)
58
Grade C$56.07+5.2% Next Q
Q3 (-1Q)
60
Grade C$58.97+6% Next Q
Current
63
Grade C$62.48+0.9% Hist 90D α
Trajectory: C (55) → C (63)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ATRC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, ATRC faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+1.08% YoY Shares) — any gross margin slip below 72.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($55.58) or 200D SMA ($38.09) invalidates the momentum regime and cuts Target Base ($63.89) toward Bear Floor ($49.83).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATRC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ATRC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ATRC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$48.3M (9% FCF Margin)
Revenue$534.5MGross Profit $400.8M (75%)Cost of Sales $133.7MOp Profit $0 (0%)OpEx (R&D/SG&A) $400.8MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $399.2M
FY24
Rev $465.3M
FY25
Rev $534.5M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$534.5M75%-1.8%-$11.4M$48.3M-1.9%
FY 2024$465.3M74.7%-8.6%-$44.7M$745.0K-7.9%
FY 2023$399.2M75%-6.7%-$30.4M$4.5M-1.9%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATRC)

  • ✓Walkthrough of ATRC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ATRC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +122.27%▲ ASCENDING CHANNEL
2026-10-30O $62.41H $62.48L $59.70C $62.48VOL 966.4K
RES: $71.12SUP: $57.48SMA50: $55.58SMA200: $38.09
$65.63$54.72$43.80$32.89$21.97RES $71.12SUP $57.48$62.482026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATRC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +14.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ATRC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATRC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ATRC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATRC)

Health Care Rank #156 of 1016 ⚔️ NVST vs ATRC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATRC vs. NVST, PLSE, IRTC, ICUI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AtriCure Inc. (ATRC) ranks #156 by composite RQD confidence (63/100, grade C) and #203 by equity capitalization ($3.18B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ATRC currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ATRC ACTIVE
AtriCure Inc.
C 63/100 — 75.0% -1.9% +1.73% $3.18B Benchmark Subject
NVST
Envista Holdings Corporation
D 49/100 84.1x 54.7% 5.1% +2.80% $3.95B /nvst-vs-atrc →
PLSE
Pulse Biosciences Inc
D- 41/100 — -30.0% -30.7% +3.37% $3.96B /plse-vs-atrc →
IRTC
iRhythm Holdings Inc.
D 48/100 — 70.6% -13.5% +3.07% $4.21B /irtc-vs-atrc →
ICUI
ICU Medical Inc.
D+ 55/100 — 36.8% 1.0% +1.36% $4.22B /icui-vs-atrc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001323885

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AtriCure Inc. (ATRC) reported GAAP revenue of $534.5M (+14.9% vs. FY2024 revenue of $465.3M , and +33.9% cumulative change since FY2023) , GAAP net income of -$11.4M, operating cash flow of $57.3M, and free cash flow of $48.3M (+6381.1% YoY). On the balance sheet, ATRC closed FY2025 with $654.2M in total assets against $61.9M in total debt (Altman Z-Score: 12.08, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $534.5M -$11.4M $57.3M $48.3M $654.2M $61.9M
FY2024 (FY) 2024-12-31 $465.3M -$44.7M $12.2M $745.0K $609.3M $61.9M
FY2023 (FY) 2023-12-31 $399.2M -$30.4M $4.5M $4.5M — —

3. ATRC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATRC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, AtriCure Inc. (NASDAQ: ATRC) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $62.48 (+1.73% 1D, market cap $3.18B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ATRC ranks #156 in composite RQD confidence.

How does ATRC compare to NVST and PLSE in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ATRC carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 75.0%, and ROIC of -1.9%. By comparison, NVST (Envista Holdings Corporation) holds a D grade (49/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.95B) and PLSE (Pulse Biosciences Inc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -30.7%, cap $3.96B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ATRC?

Per ATRC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001323885), AtriCure Inc. generated $534.5M in revenue (+14.9% YoY), -$11.4M in net income, and $48.3M in free cash flow against $654.2M in total assets and $61.9M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ATRC trading relative to its 50-day, 200-day, and 52-week technical levels?

ATRC last traded at $62.48 (+1.73% on volume of 702,406 shares), positioning the stock +12.41% above its 50-day simple moving average ($55.58) and +64.03% above its 200-day simple moving average ($38.09). Across its 52-week range of $25.36 to $63.00, ATRC sits at the 98.6% percentile with a 14-day RSI of 62.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.1% ($57.42 to $67.54).

ATRC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is AtriCure Inc. (ATRC)?

In FY 2025 (10-K), ATRC converted $534.5M of revenue into a 75% gross margin, 0% operating margin, and $48.3M in free cash flow (9% FCF margin).

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%